Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)

Summary

The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons), a drug used to treat Alzheimer´s disease, on the progression of Amyotrophic Lateral Sclerosis (ALS). Memantine is added to riluzole (the single drug approved to treat ALS).

Timeline

Start

2005-07

Primary completion

2008-06

Completion

2009-01

Drugs

Indications